Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20
- Telecommunications Equip
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 1804
IPSCIO Record ID: 2882
IPSCIO Record ID: 286035
The Licensor of Ireland shall remain proprietor of the Licensors Glucose Monitor Technology but grants to Licensee for the term a sole and exclusive license in the territory, with the right to grant sublicenses, to research, develop, manufacture, have manufactured for Licensee, import and have imported, use, sell, offer for sale and otherwise commercialize the Glucose Monitor Technology, Licensors interest in the joint improvements in the field and the products.
Licensor grants an exclusive license in the territory solely for use in connection with the sale of the product, for the term to use any Licensor trademark, if any, which relates to the Licensors Glucose Monitor Technology applicable to the product.
This agreement includes a non-exclusive grant back to Licensor from Licensee.
Licensor is knowledgeable in the development of devices and methods for directly or indirectly monitoring the concentration of glucose in a subject and has developed unique monitoring devices and methods.
The patents are for Analyte Controlled Liquid Delivery Device and Analyte Monitor; and, Improved Glucose Monitor.
IPSCIO Record ID: 2288
IPSCIO Record ID: 7799
IPSCIO Record ID: 6495
IPSCIO Record ID: 289542
6,970,742 – Method for detecting, diagnosing, and treating cardiovascular disease
6,328,699 – Permanently implantable system and method for detecting, diagnosing and treating congestive heart failure
IPSCIO Record ID: 26989
IPSCIO Record ID: 406
IPSCIO Record ID: 180208
IPSCIO Record ID: 7548
IPSCIO Record ID: 268269
IPSCIO Record ID: 779
U.S. and PCT Pending Applications
Tab Filing Date Application No. Title JFM Reference
1 26-May-2006 60/803,289 Compact Minimally-Invasive Biomedical Monitor 92329.052206US
2 11-April-2006 11/279,290 Blood Monitoring Systems and Methods Thereof 92329.l47l05US2
3 11-April-2006 PCT/US2006/l3443 Blood Monitoring Systems and Methods Thereof 92329.147105PCT
4 30-June-2006 PCT/US2006/26l05 Non-Invasive, Spectral, Glucose Monitoring Systems and Methods Thereof 92329.147205PCT
5 25-April-2006 11/380,063 Microneedle With Glucose Sensor and Methods Thereof 92329.147305US2
6 25-April-2006 PCT/US2006/l5356 Microneedle With Glucose Sensor and Methods Thereof 92329.147305PCT
7 11-July-2006 PCT/US2006/26774 Minimally Invasive Allergy Testing Systems and Methods Thereof 92329.l47805PCTl
8 11-July-2006 PCT/US2006/26734 Minimally Invasive Allergy Testing Systems and Methods Thereof 92329.147805PCT2
9 PCT/US2007/6l604 Minimally Invasive Allergy Testing with Coated Allergen
10 Allergy Testing Cartridge with Coated Allergens 92329.0l0l07PCT
IPSCIO Record ID: 27452
The Company has the exclusive U.S. marketing rights and license for an ambulatory infusion–a round, spring-driven infusion pump with dedicated administration sets and related accessories which also includes an electronic alarm to denote the completion of an infusion.
IPSCIO Record ID: 26581
The AERx iDMS is being designed as a painless and convenient alternative to insulin injection. This should enable patients with diabetes to comply more effectively with their insulin therapy, thereby reducing the risk of long-term complications. AERx iDMS is being developed to control blood glucose levels in patients with diabetes.
IPSCIO Record ID: 144368
The artificial extracellular oxygen carriers are capable of human organ support in cases of acute and chronic lack of oxygen or blood loss due to surgery, accident, arterial occlusion, anemia or other causes.
The implantable glucose sensor is for day and night monitoring of a patients glucose level.
IPSCIO Record ID: 1666
IPSCIO Record ID: 7157
Seller, in conjunction with its development partner (a third party) has developed the GlucoChipâ„¢, a product designed to measure blood glucose levels in vivo. This product is based on the intellectual property (patents, patents pending and other intellectual property) being sold to Buyer as a part of this agreement. Simultaneously with the execution of this agreement, the parties will enter into a License Agreement whereby Buyer will grant a license to Seller regarding and including the GlucoChipâ„¢.
Description of Assets. Upon the terms and subject to the conditions hereof, on the Closing Date, Seller shall sell, transfer, assign and deliver to Buyer, and Buyer shall purchase from Seller, all of Sellerâ€™s right, title and interest in and to all of Sellerâ€™s assets that are limited to the operation of the Business in the RFID Field, including, without limitation, the following assets (collectively referred to as the Purchased Assets) which shall be conveyed in the manner described The patents and patent applications, including divisions, continuations, renewals, reissuances, and extensions of the foregoing (as applicable) listed in this Agreement shall be transferred and assigned to Buyer (the Assigned Patents), pursuant to an assignment of patent, and Seller shall receive from Buyer a full and irrevocable covenant not to sue for Seller's use of such patents and patent applications pursuant to the License Agreement between Seller and Buyer dated August 28, 2012.
7,125,382 Embedded Bio-Sensor System
7,297,112 Embedded Bio-Sensor System
2008/0033273 Embedded Bio-Sensor System
7,241,266 Transponder for Embedded Bio-Sensor using Body Energy as a Power Source
The implantable RFID device is protected under United States Patent No. 7,125,382, Embedded Bio Sensor System for the purpose of designing and constructing, using, selling and offering to sell products or services related to the Licensee business, but excluding the GlucoChip, or any product or application involving blood glucose detection or diabetes management.
Embedded bio-sensor system – Provided is a bio-sensor system which utilizes radio frequency identification technology and which includes a remote transponder in wireless communication with an implantable passively-powered on-chip transponder. The bio-sensor system is specifically adapted to provide a substantially stable and precise sensor reference voltage to a sensor assembly that is included with the on-chip transponder.
The remote transponder is also configured to remotely receive data representative of a physiological parameter of the patient as well as identification data and may enable readout of one or more of the physiological parameters that are measured, processed and transmitted by the on-chip transponder upon request by the remote transponder. The precision and stability of the sensor reference voltage is enhanced by the specific circuit architecture of the glucose sensor to allow for relatively accurate measurement of the physiological parameter such as measurement of glucose concentration by a glucose sensor without the use of a microprocessor.
IPSCIO Record ID: 25900
Markets means Diagnostics – an Implantable Glucose Sensing Device for use in the human body markets, the animal markets, and applicational areas in the Field.
IPSCIO Record ID: 372589
For the Trademarks, Licensee may use the Trademarks solely as necessary to use, offer for sale, sell, lease and/or import the Product in accordance with the terms and conditions of this Agreement.
Product means Licensors proprietary technology known as the Symphonyâ„¢ tCGM System, including any next-generation products that are substantially based upon or incorporate improvements to the Symphonyâ„¢ tCGM System.
The trademarks mean Prelude, Prelude SkinPrep, Symphony, and, Symphony tCGM.
Patents are titled Skin Permeation Device for Analyte Sensing or Transdermal Drug Delivery; and, Transdermal Analyte Monitoring Systems and Methods for Analyte Detection.
Licensor product development is for use in clinical settings and by people with diabetes.